Welcome to our dedicated page for Lifeward SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lifeward Ltd. (Nasdaq: LFWD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Lifeward is a medical device company focused on rehabilitation technologies such as the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System, and it is incorporated in the State of Israel with ordinary shares listed on the Nasdaq Capital Market.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss Lifeward’s product portfolio, geographic operations in the United States, Israel, and Germany, reimbursement developments for personal exoskeletons, and risk factors relevant to its medical technology business. AI tools highlight key sections, such as discussions of CMS reimbursement pathways, international sales, and operational initiatives.
Lifeward’s current reports on Form 8-K are especially important for tracking material events. Recent 8-K filings describe a Nasdaq bid-price deficiency notice, a secured promissory note and loan agreement with Oramed Ltd., preliminary financial results, the appointment of a new Chief Financial Officer, the approval of a 2025 Incentive Compensation Plan, and the results of the 2025 annual shareholder meeting. AI summaries surface the main terms of these events, including financing structures, compliance timelines, and governance changes.
Investors can also monitor registration statements such as the Form S-1 and S-1/A related to offerings of ordinary shares and warrants. These documents outline Lifeward’s status as a smaller reporting company, describe the securities being offered, and provide additional detail on use of proceeds and capital structure. Where applicable, the platform also surfaces insider transaction reports on Form 4 to show equity awards or share dealings by directors and officers, if and when such filings are made.
All filings are sourced in real time from the SEC’s EDGAR system. AI-powered analysis helps explain technical language, highlight covenant and dilution terms in financing agreements, and point out items that may affect shareholders of LFWD, without replacing a careful reading of the original documents.
Lifeward has received SEC approval for its Form S-1 registration statement, which became effective on June 25, 2025, at 9:00 A.M. The Form S-1 (File Number: 333-288172) marks a significant milestone as it indicates the company's intention to conduct an initial public offering (IPO).
This Notice of Effectiveness (EFFECT filing) confirms that Lifeward can now proceed with its planned public offering of securities. The company, identified by CIK number 0001607962, has completed the SEC review process and received regulatory clearance to move forward with its IPO plans.
Key points for investors:
- Form S-1 registration statement is now active
- Company can commence its IPO process
- Trading symbol will be LFWD
- Securities can be offered to the public following the effectiveness date
Lifeward has filed an amended S-1 registration statement for a proposed public offering of up to 4,000,000 ordinary shares at an assumed price of $1.07 per share, along with accompanying warrants. The offering includes:
- Warrants to purchase up to 4,000,000 ordinary shares at $1.07 per exercise price
- Pre-funded warrants available for investors who would exceed 4.99% ownership
- Placement Agent Warrants to purchase up to 240,000 ordinary shares
- Total of up to 8,240,000 ordinary shares issuable upon exercise of all warrants
H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 7% cash fee plus 1% management fee. The offering will terminate on July 30, 2025 unless ended earlier. Lifeward trades on Nasdaq Capital Market under symbol "LFWD" and qualifies as a smaller reporting company. The company is headquartered in Marlborough, MA with incorporation in Israel. Proceeds will be immediately available for use with no minimum offering amount required.
Lifeward, an Israeli medical device company (NASDAQ: LFWD), has filed an S-1 registration statement for a public offering of up to 4,000,000 ordinary shares and warrants. The offering includes:
- Ordinary shares with accompanying warrants at an assumed price of $1.07 per unit
- Pre-funded warrants with accompanying warrants for investors exceeding 4.99%/9.99% ownership threshold
- Warrants exercisable at $1.07 per share with 5-year term
- 240,000 placement agent warrants (6% of offering)
Key details: The company is a smaller reporting company and non-accelerated filer. The offering will terminate on July 30, 2025, with no minimum offering amount required. Proceeds will be immediately available for use. The placement agent will receive a 7% cash fee plus 1% management fee. Trading warrants will not be listed on any exchange.
Risks include: No escrow arrangements, no minimum offering amount, immediate use of proceeds without guarantee of achieving business objectives.